Oral Ciprofloxacin Effective for Treatment of Human Plague

Share this content:
Oral Ciprofloxacin Effective for Treatment of Human Plague
Oral Ciprofloxacin Effective for Treatment of Human Plague

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Oral ciprofloxacin is effective for the treatment of human plague, caused by Yersinia pestis, according to research published in the March issue of the U.S. Centers for Disease Control and Prevention's Emerging Infectious Diseases.

Titus Apangu, from the Uganda Research Institute in Entebbe, and colleagues examined the efficacy and safety of ciprofloxacin for treatment of plague. Patients with suspected plague seen at six clinics and two hospitals in the West Nile region of Uganda were offered enrollment in a study. Diagnostic samples were collected and oral ciprofloxacin was administered for 10 days. The authors enrolled five patients with culture-confirmed plague who were treated with oral ciprofloxacin: three were admitted and two were treated as outpatients. Four patients had bubonic plague and one had pneumonic plague.

The researchers found that all patients received ciprofloxacin and acetaminophen and two received a bolus of normal saline. Within two days, all patients became afebrile. All had been discharged and had returned to their normal activities at 14 days. No complications were identified.

"Our results add to growing clinical experience and support the broader use of oral ciprofloxacin for treatment of human plague, especially in resource-poor areas where intravenous treatment is limited," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »